Cardiff Oncology (CRDF) Set to Post Earnings on Thursday

Cardiff Oncology (NASDAQ:CRDF) is expected to be issuing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.1380) per share and revenue of $0.08 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). Cardiff Oncology had a negative return on equity of 103.10% and a negative net margin of 7,885.43%. The business had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.06 million. On average, analysts expect Cardiff Oncology to post ($0.60) EPS for the current fiscal year and ($0.56) EPS for the next fiscal year.

Cardiff Oncology Price Performance

Shares of Cardiff Oncology stock opened at $0.90 on Thursday. Cardiff Oncology has a 1 year low of $0.76 and a 1 year high of $3.31. The firm’s 50-day moving average is $1.08 and its two-hundred day moving average is $1.47. The stock has a market cap of $69.82 million, a price-to-earnings ratio of -1.50 and a beta of 1.42.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CRDF. HC Wainwright raised shares of Cardiff Oncology from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 15th. William Blair downgraded shares of Cardiff Oncology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, August 11th. Weiss Ratings lowered shares of Cardiff Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 23rd. Finally, Wall Street Zen raised shares of Cardiff Oncology from a “strong sell” rating to a “sell” rating in a report on Saturday, September 5th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $7.50.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead product candidate is onvansertib, an oral, selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cancer-cell division.

Cardiff Oncology has primarily evaluated onvansertib in combination with standard treatments for patients with RAS-mutated metastatic colorectal cancer, including investigations involving KRAS-mutated disease. The company has also explored the candidate in other solid tumors, including metastatic castration-resistant prostate cancer.